Moderna Vaccine Production Shift Down: Focus on Growth in a Post-Pandemic Era

Moderna Vaccine Production Shift Down: Due to decreased demand, Moderna is producing fewer COVID-19 vaccines. The goal is to increase the gross margin by 75%–80%. Moderna is discussing ways to accelerate the production of its mRNA-based COVID-19 vaccines with global partners. Partners package the vaccines.

Due to the disease’s prevalence, this reduction plan is a response. Fewer people will want shots as fewer people order them. Moderna expected 50-100 million vaccine doses for the U.S. in the fall. Billions of doses were made annually during the pandemic. With FDA approval, Moderna will distribute the vaccine nationwide. Deals are set to ship to the UK, Canada, and Japan. Talks with the EU are ongoing.

Moderna is developing vaccines for COVID, RSV, and influenza. Discussing with other vaccine makers about these new medicines may take around a year. These deals will likely shape Moderna’s future and ensure its position in the vaccine market for a long time.

Moderna is updating its RSV shot, proving its flu vaccine’s effectiveness for all age groups, including older individuals. In late-stage tests, the flu shot outperformed regular treatments. In an early study, it matched or surpassed Sanofi’s high-dose flu vaccine.

Moderna’s evolving strategy in the post-pandemic era strengthens its position in the vaccine market.

ALSO READ: AI Generated COVID Drug Enters Trials: Potential Effectiveness Against All Variants

Our Reader’s Queries

Is the Moderna shot being discontinued?

The Bivalent version of the Moderna COVID-19 Vaccine is no longer permitted for use in the US. However, the Moderna COVID-19 Vaccine (2023-2024 Formula) has been authorized for use in the following manner: Unvaccinated individuals aged 6 months to 4 years will receive two doses of the vaccine.

What are the results of Moderna 2023?

In Q3 2023, net product sales took a hit, dropping by 44% compared to the same period in 2022. This was mainly due to lower sales volume, but a higher average selling price helped to offset some of the losses. Meanwhile, the cost of sales for the quarter was $2.2 billion.

Where is Moderna produced?

Moderna, a US biotech firm, has recently announced its plans to construct an mRNA vaccine manufacturing plant in Victoria, marking the first of its kind in the Southern Hemisphere. The company has reached an in-principle agreement and is expected to produce up to 100 million vaccine doses annually in Australia. This move is a significant step towards strengthening the country’s vaccine production capabilities and ensuring a steady supply of vaccines to the population.

What is the market share of Moderna COVID?

Moderna has emerged as a dominant player in the U.S. COVID-19 market, surpassing its rival Pfizer (PFE.N) with a market share of 48% in the fall season of 2023, up from 37% in 2022. The company’s success can be attributed to its strong partnerships with pharmacies, which have played a crucial role in expanding its market share.

Leave a Reply

Your email address will not be published. Required fields are marked *